StockNews.com Begins Coverage on Vanda Pharmaceuticals (NASDAQ:VNDA)

Stock analysts at StockNews.com started coverage on shares of Vanda Pharmaceuticals (NASDAQ:VNDA) in a note issued to investors on Tuesday. The firm set a “hold” rating on the biopharmaceutical company’s stock.

Separately, HC Wainwright restated a “buy” rating and set a $18.00 price target on shares of Vanda Pharmaceuticals in a research note on Tuesday, January 21st.

Vanda Pharmaceuticals Price Performance

VNDA opened at $4.53 on Tuesday. The company has a market capitalization of $264.14 million, a PE ratio of -16.18 and a beta of 0.77. Vanda Pharmaceuticals has a fifty-two week low of $3.46 and a fifty-two week high of $6.75. The business has a 50-day moving average of $4.72 and a 200-day moving average of $4.98.

Insider Activity

In related news, Director Stephen Ray Mitchell sold 5,000 shares of the business’s stock in a transaction on Thursday, November 14th. The shares were sold at an average price of $5.17, for a total transaction of $25,850.00. Following the transaction, the director now owns 44,857 shares of the company’s stock, valued at approximately $231,910.69. The trade was a 10.03 % decrease in their ownership of the stock. The sale was disclosed in a legal filing with the SEC, which is available through this hyperlink. Insiders own 8.90% of the company’s stock.

Institutional Trading of Vanda Pharmaceuticals

Several hedge funds and other institutional investors have recently bought and sold shares of VNDA. ORG Wealth Partners LLC bought a new position in Vanda Pharmaceuticals during the third quarter valued at about $40,000. China Universal Asset Management Co. Ltd. boosted its stake in Vanda Pharmaceuticals by 64.0% during the third quarter. China Universal Asset Management Co. Ltd. now owns 11,211 shares of the biopharmaceutical company’s stock worth $53,000 after buying an additional 4,374 shares in the last quarter. XTX Topco Ltd bought a new stake in Vanda Pharmaceuticals in the 2nd quarter valued at $75,000. Intech Investment Management LLC acquired a new position in shares of Vanda Pharmaceuticals in the 3rd quarter valued at $84,000. Finally, SG Americas Securities LLC boosted its position in shares of Vanda Pharmaceuticals by 88.5% during the 3rd quarter. SG Americas Securities LLC now owns 20,402 shares of the biopharmaceutical company’s stock valued at $96,000 after acquiring an additional 9,580 shares in the last quarter. 88.14% of the stock is currently owned by institutional investors and hedge funds.

Vanda Pharmaceuticals Company Profile

Vanda Pharmaceuticals Inc, a biopharmaceutical company, focuses on the development and commercialization of therapies to address high unmet medical needs worldwide. The company’s marketed products include HETLIOZ to treat non-24-hour sleep-wake disorders; and Fanapt oral tablets for the treatment of schizophrenia.